Publications & Reports

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.

Apostolopoulos V, Pietersz GA, McKenzie IF
Austin Research Institute, Heidelberg, Victoria, Australia.

Abstract

The immunotherapy of cancer requires the definition of a suitable target for and the induction of a CD8+ cytotoxic lymphocyte reaction. In breast cancer, particularly mucins (MUC1) of the variable number of tandem repeat sequence may be a suitable target, but there has been a problem in inducing a cytotoxic response. MUC1 peptides, conjugated to carriers (keyhole-limpet hemocyanin or diphtheria toxoid) induce a humoral response and give poor tumor protection in mice and there is little cellular immunity. However, when MUC1 fusion protein is conjugated to mannan under oxidizing conditions, a cellular immune response is induced, with significant tumor protection, cytotoxic T lymphocytes and little antibody. The procedure may also be useful for other antigens.

Publication

  • Journal: Vaccine
  • Published: 01/06/1996
  • Volume: 14
  • Issue: 9
  • Pagination: 930-938